BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 20360661)

  • 1. Plerixafor (Mozobil).
    Med Lett Drugs Ther; 2010 Apr; 52(1335):27-8. PubMed ID: 20360661
    [No Abstract]   [Full Text] [Related]  

  • 2. Plerixafor.
    DiPersio JF; Uy GL; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2009 Feb; 8(2):105-6. PubMed ID: 19180104
    [No Abstract]   [Full Text] [Related]  

  • 3. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
    Lor KW; Helmons PJ; Belew H; Lane JR; Ball ED
    Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plerixafor: a peripheral blood stem cell mobilizer.
    Kessans MR; Gatesman ML; Kockler DR
    Pharmacotherapy; 2010 May; 30(5):485-92. PubMed ID: 20411999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
    Steinberg M; Silva M
    Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization.
    Dugan MJ; Maziarz RT; Bensinger WI; Nademanee A; Liesveld J; Badel K; Dehner C; Gibney C; Bridger G; Calandra G
    Bone Marrow Transplant; 2010 Jan; 45(1):39-47. PubMed ID: 19483760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experience.
    Basak GW; Knopinska-Posluszny W; Matuszak M; Kisiel E; Hawrylecka D; Szmigielska-Kaplon A; Urbaniak-Kujda D; Dybko J; Zielinska P; Dabrowska-Iwanicka A; Werkun J; Rzepecki P; Wroblewska W; Wiktor-Jedrzejczak W
    Ann Hematol; 2011 May; 90(5):557-68. PubMed ID: 20938660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization.
    Smith VR; Popat U; Ciurea S; Nieto Y; Anderlini P; Rondon G; Alousi A; Qazilbash M; Kebriaei P; Khouri I; de Lima M; Champlin R; Hosing C
    Am J Hematol; 2013 Sep; 88(9):754-7. PubMed ID: 23749720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
    Li J; Hamilton E; Vaughn L; Graiser M; Renfroe H; Lechowicz MJ; Langston A; Prichard JM; Anderson D; Gleason C; Lonial S; Flowers CR; Kaufman JL; Waller EK
    Transfusion; 2011 Oct; 51(10):2175-82. PubMed ID: 21492180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toward a more rational policy for autologous hematopoietic stem cell mobilization.
    Devine SM
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1468-70. PubMed ID: 22892553
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience.
    Jantunen E; Kuittinen T; Mahlamäki E; Pyörälä M; Mäntymaa P; Nousiainen T
    Eur J Haematol; 2011 Apr; 86(4):299-304. PubMed ID: 21198864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plerixafor and granulocyte-colony-stimulating factor for mobilization of hematopoietic stem cells for autologous transplantation in Chinese patients with non-Hodgkin's lymphoma: a randomized Phase 3 study.
    Zhu J; Huang H; Chen H; Zhang X; Li Z; Wu D; Zhou D; Song Y; Hu Y; Liang Y; Ren H; Huang H; Li N; Chen H; Hu J; Li J; Meng R; Wu J; Yu D; Huang X
    Transfusion; 2018 Jan; 58(1):81-87. PubMed ID: 29238988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.
    Micallef IN; Stiff PJ; Nademanee AP; Maziarz RT; Horwitz ME; Stadtmauer EA; Kaufman JL; McCarty JM; Vargo R; Cheverton PD; Struijs M; Bolwell B; DiPersio JF
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1187-1195. PubMed ID: 29410180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma.
    Stiff PJ; Micallef I; Nademanee AP; Stadtmauer EA; Maziarz RT; Bolwell BJ; Bridger G; Marulkar S; Hsu FJ; DiPersio JF
    Biol Blood Marrow Transplant; 2011 Aug; 17(8):1146-53. PubMed ID: 21126595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data.
    Duarte RF; Shaw BE; Marín P; Kottaridis P; Ortiz M; Morante C; Delgado J; Gayoso J; Goterriz R; Martínez-Chamorro C; Mateos-Mazón JJ; Ramírez C; de la Rubia J; Achtereekte H; Gandhi PJ; Douglas KW; Russell NH
    Bone Marrow Transplant; 2011 Jan; 46(1):52-8. PubMed ID: 20305700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation.
    Brave M; Farrell A; Ching Lin S; Ocheltree T; Pope Miksinski S; Lee SL; Saber H; Fourie J; Tornoe C; Booth B; Yuan W; He K; Justice R; Pazdur R
    Oncology; 2010; 78(3-4):282-8. PubMed ID: 20530974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safe and effective use of plerixafor plus G-CSF in dialysis-dependent renal failure.
    Pinto V; Castelli A; Gaidano G; Conconi A
    Am J Hematol; 2010 Jun; 85(6):461-2. PubMed ID: 20513130
    [No Abstract]   [Full Text] [Related]  

  • 18. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
    Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mobilization of peripheral blood stem cells with plerixafor in poor mobilizer patients].
    Sancho JM; Duarte R; Medina L; Querol S; Marín P; Sureda A;
    Med Clin (Barc); 2016 Sep; 147(5):223.e1-223.e7. PubMed ID: 27374031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mobilization of hematopoietic stem cells into the peripheral blood.
    Damon LE; Damon LE
    Expert Rev Hematol; 2009 Dec; 2(6):717-33. PubMed ID: 21082960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.